Mitochondrial metabolism as a dynamic regulatory hub to malignant transformation and anti-cancer drug resistance

被引:5
|
作者
Tomar, Manendra Singh [1 ]
Kumar, Ashok [2 ]
Shrivastava, Ashutosh [1 ]
机构
[1] King Georges Med Univ, Fac Med, Ctr Adv Res, Lucknow 226003, Uttar Pradesh, India
[2] All India Inst Med Sci AIIMS Bhopal, Dept Biochem, Bhopal 462020, Madhya Pradesh, India
关键词
Cancer; Mitochondria; Metabolism; Drug resistance; Oxidative phosphorylation; TCA cycle; Electron transport chain; CYTOCHROME-C-OXIDASE; ONE-CARBON METABOLISM; FATTY-ACID SYNTHASE; SEROLOGICAL DIAGNOSTIC BIOMARKERS; ASPARAGINE SYNTHETASE EXPRESSION; ISOCITRATE DEHYDROGENASE 1; CANCER-CELL METABOLISM; TUBULIN BETA-CHAIN; BREAST-CANCER; GLUTAMINE-METABOLISM;
D O I
10.1016/j.bbrc.2023.149382
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Glycolysis is the fundamental cellular process that permits cancer cells to convert energy and grow anaerobically. Recent developments in molecular biology have made it evident that mitochondrial respiration is critical to tumor growth and treatment response. As the principal organelle of cellular energy conversion, mitochondria can rapidly alter cellular metabolic processes, thereby fueling malignancies and contributing to treatment resistance. This review emphasizes the significance of mitochondrial biogenesis, turnover, DNA copy number, and mutations in bioenergetic system regulation. Tumorigenesis requires an intricate cascade of metabolic pathways that includes rewiring of the tricarboxylic acid (TCA) cycle, electron transport chain and oxidative phosphorylation, supply of intermediate metabolites of the TCA cycle through amino acids, and the interaction between mitochondria and lipid metabolism. Cancer recurrence or resistance to therapy often results from the cooperation of several cellular defense mechanisms, most of which are connected to mitochondria. Many clinical trials are underway to assess the effectiveness of inhibiting mitochondrial respiration as a potential cancer therapeutic. We aim to summarize innovative strategies and therapeutic targets by conducting a comprehensive review of recent studies on the relationship between mitochondrial metabolism, tumor development and therapeutic resistance.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] The FGF/FGFR signalling mediated anti-cancer drug resistance and therapeutic intervention
    Mahapatra, Subhasmita
    Jonniya, Nisha Amarnath
    Koirala, Suman
    Ursal, Kapil Dattatray
    Kar, Parimal
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2023, 41 (22) : 13509 - 13533
  • [42] H1Innovative approaches to combat anti-cancer drug resistance: Targeting lncRNA and autophagy
    Zhong, Chenming
    Xie, Zijun
    Duan, Shiwei
    CLINICAL AND TRANSLATIONAL MEDICINE, 2023, 13 (10):
  • [43] Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference
    Tan, Daniel S. -W.
    Gerlinger, Marco
    Teh, Bin-Tean
    Swanton, Charles
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (12) : 2166 - 2177
  • [44] Lipid metabolism as a target for cancer drug resistance: progress and prospects
    Wang, Zi'an
    Wang, Yueqin
    Li, Zeyun
    Xue, Wenhua
    Hu, Shousen
    Kong, Xiangzhen
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [45] Uptake of collagen type I via macropinocytosis cause mTOR activation and anti-cancer drug resistance
    Yamazaki, Shota
    Su, Yinghan
    Maruyama, Ami
    Makinoshima, Hideki
    Suzuki, Jun
    Tsuboi, Masahiro
    Goto, Koichi
    Ochiai, Atsushi
    Ishii, Genichiro
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 526 (01) : 191 - 198
  • [46] Acridine Orange is an Effective Anti-Cancer Drug that Affects Mitochondrial Function in Osteosarcoma Cells
    Fotia, Caterina
    Avnet, Sofia
    Kusuzaki, Katsuyuki
    Roncuzzi, Laura
    Baldini, Nicola
    CURRENT PHARMACEUTICAL DESIGN, 2015, 21 (28) : 4088 - 4094
  • [47] Hsp90 inhibitors and drug resistance in cancer: The potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs
    Lu, Xiangyi
    Xiao, Li
    Wang, Luan
    Ruden, Douglas M.
    BIOCHEMICAL PHARMACOLOGY, 2012, 83 (08) : 995 - 1004
  • [48] Synthesis and anti-cancer evaluation of folic acid-peptide- paclitaxel conjugates for addressing drug resistance
    Dai, Yuxuan
    Cai, Xingguang
    Bi, Xinzhou
    Liu, Chunxia
    Yue, Na
    Zhu, Ying
    Zhou, Jiaqi
    Fu, Mian
    Huang, Wenlong
    Qian, Hai
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 171 : 104 - 115
  • [49] METFORMIN - FROM ANTI-DIABETIC DRUG TO ANTI-CANCER DRUG
    Markowicz-Piasecka, Magdalena
    Huttunen, Kristiina M.
    Mikiciuk-Olasik, Elzbieta
    Mateusiak, Lukasz
    Sikora, Joanna
    ACTA POLONIAE PHARMACEUTICA, 2018, 75 (01): : 3 - 18
  • [50] Anti-angiogenic drugs: direct anti-cancer agents with mitochondrial mechanisms of action
    Quayle, Lewis A.
    Pereira, Maria G.
    Scheper, Gerjan
    Wiltshire, Tammy
    Peake, Ria E.
    Hussain, Issam
    Rea, Carol A.
    Bates, Timothy E.
    ONCOTARGET, 2017, 8 (51) : 88670 - 88688